GC History

2022

1. GC Genome awarded Good Clinical Laboratory Practice(GCLP)
   status
2. GC - GC Cell acquires BioCentriq in US

2021

1. GC Wellbeing completes contruction on innovation plant in
   Eumseong, Chungbuk
2. UBCare's "With Doctor(의사랑)" awarded EMR national standard
   by Ministry of Health and Welfare
3. GC acquires Geneslab
4. GC LabCell - GC Cell merges together under integrated company
   GC Cell
5. GC LabCell joins hands with Artiva MSD to export X trillion-sized
   CAR-NK technology
6. GC Biopharma obtains product license for the world’s first
   severe Hunter syndrome treatment [Hunterase ICV] in Japan,
   and for a recombinant treatment for hemophilia [Greengene F]
   in China.

2020

1. Established GreenVet
2. GCLabs designated as the first in vitro diagnostic medical device
   clinical performance testing institution in Korea
3. GC Care acquires AbleAnalytics
4. GC Biopharma obtains product license for [Barycela], a next
   generation varicella vaccine GC Biopharma obtains first product
   license in China for [Hunterase] to treat Hunter Syndrome
5. GC Care acquires UBCare

2019

1. GC Wellbeing successfully completes IPO
2. Establishment of GCCL

2018

1. Corporate name changed to “GC”
2. GC Biopharma receives <200 Million USD Export Tower> Award
3. GC Cell completes Cell Center

2017

1. Establishement of Curevo
2. GC Genome acquires CAP certification

2016

1. GC Biopharma's GCFLU Quadrivalent becomes second in the
   world to pass WHO prequalification
2. GC Biopharma obtains product license of [GC TD Vaccine],
   Korea’s first DPT (Diphtheria, Pertussis, and Tetanus) vaccine
3. GC Cell successfully completes IPO

2015

1. GCMS acquires CeragemMedisys (GCMedis) and begins
   operations on diabetes business
2. GC Labs awarded <2015 Korea ICT Innovation> Grand Prize by
   Minister of Science, ICT and Future Planning
3. GC Biopharma becomes fourth company in the world to obtain
   product license for quadrivalent seasonal flu vaccine
   [GCFLU Quadrivalent]
4. GC Biopharma becomes first company in Korea to obtain product
   license for H5N1 (avian flu) vaccine [GCFLU H5N1]

2014

1. GCMS successfully completes IPO
2. GCMS becomes first company in the world to obtain product
   license for multiple diagnosis influenza diagnostic kit
3. GC Biopharma surpasses over 100 million doses of GCFLU
   production
4. GC Biopharma receives <100 Million USD Export Tower> Award

2013

1. Established GC Genome
2. GCMS merges with Gambro Korea Solution, begins hemodialysis
   business
3. GC Biopharma begins construction on blood plasma fractionation
   plant in Thailand (with Thai Red Cross) Completion of
   GC R&D Center, the largest scale R&D center among
   pharmaceutical industry in Korea

2012

1. GC Biopharma becomes second company in the world to obtain
   product license for Hunter syndrome treatment [Hunterase]
2. GC Cell established as a result of acquiring Innocell

2011

1. Established GC LabCell
2. GC Biopharma obtaines product license for natural medicine
   osteoarthritis treatment [Sinbaro]

2009

1. Established the Future Foundation of Korea
2. GC Biopharma completes construction of Korea's first vaccine-
   exclusive Hwasun plant
3. GC Biopharma obtaines product license for H1N1 influenza
   vaccine [GREEN FLU] and Korea’s first trivalent flu vaccine
   [GCFLU]
4. GC Biopharma completes construction of Ochang plant,
   a state-of-the-art blood product and gene
   recombination production facility

2008

1. GC Biopharma becomes fourth company in the world to obtain
   product license for recombinant hemophilia-A treatment
   (GreenGene)

2007

1. Established GCInvacfarm

2006

1. GCMS acquires product license for magnetic diagnostic reagent
   for the first time in Korea

2005

1. Established the Mogam Science Scholarship Foundation
2. GC Wellbeing obtaines product license for placenta injection
   [Laennec]

2004

1. Established GC Wellbeing

2003

1. Established GS MS
2. Established GCHealthcare

2001

1. Established GCEM
2. GC Biopharma acquires Sang-A Pharmaceuticals

2000

1. Completes construction of Jeongseong Green Cross
   Pharmaceutical Center and plant

1995

1. Established GCChina, Anhui Green Cross Bio Products Limited
   in China Completion of vaccine plant in Indonesia

1993

1. Becomes second company in the world to obtain product
   license for varicella vaccine [Suduvax]

1990

1. Launched Green Friends Association
2. Mogam Science Scholarship Foundation achieves product
   license for AIDS diagnostic reagent

1989

1. GC Biopharma successfully completes IPO

1988

1. Becomes first pharmaceutical company in the world to obtain
   product license for vaccine against hemorrhagic fever with
   renal syndrome [Hantavax]

1984

1. Established Green Cross Research Center
   (now Mogam Institute of Biomedical Research)

1983

1. Becomes third pharmaceutical company in the world to obtain
   product license for hepatitis-B vaccine [Hepavax-B]

1982

1. Established GCLabs, obtains product license for IVIG [I.V.-Globulin]

1978

1. GC successfully completes IPO

1974

1. Obtains product license for anti-hemophilic factor [AHF]

1973

1. Obtains product license for Korea’s first stroke treatment
   [Urokinase]

1971

1. Name change to Green Cross BioPharma Incorporated
   Completion of first blood plasma fractionation plant

1968

1. Completion of Singal plant

1967

1. Established as Sudo Microorganism Medical Supplies Company